255 related articles for article (PubMed ID: 21275455)
1. Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.
Shiroiwa T; Motoo Y; Tsutani K
Mol Diagn Ther; 2010 Dec; 14(6):375-84. PubMed ID: 21275455
[TBL] [Abstract][Full Text] [Related]
2. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
[TBL] [Abstract][Full Text] [Related]
4. KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.
Blank PR; Moch H; Szucs TD; Schwenkglenks M
Clin Cancer Res; 2011 Oct; 17(19):6338-46. PubMed ID: 21807639
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for third and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer.
Hoyle M; Peters J; Crathorne L; Jones-Hughes T; Cooper C; Napier M; Hyde C
Value Health; 2013; 16(2):288-96. PubMed ID: 23538180
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany.
Vijayaraghavan A; Efrusy MB; Göke B; Kirchner T; Santas CC; Goldberg RM
Int J Cancer; 2012 Jul; 131(2):438-45. PubMed ID: 21898389
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation testing of tumours in adults with metastatic colorectal cancer: a systematic review and cost-effectiveness analysis.
Westwood M; van Asselt T; Ramaekers B; Whiting P; Joore M; Armstrong N; Noake C; Ross J; Severens J; Kleijnen J
Health Technol Assess; 2014 Oct; 18(62):1-132. PubMed ID: 25314637
[TBL] [Abstract][Full Text] [Related]
8. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
[TBL] [Abstract][Full Text] [Related]
9. Economic Analysis of Panitumumab Compared With Cetuximab in Patients With Wild-type KRAS Metastatic Colorectal Cancer That Progressed After Standard Chemotherapy.
Graham CN; Maglinte GA; Schwartzberg LS; Price TJ; Knox HN; Hechmati G; Hjelmgren J; Barber B; Fakih MG
Clin Ther; 2016 Jun; 38(6):1376-1391. PubMed ID: 27085587
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer.
Behl AS; Goddard KA; Flottemesch TJ; Veenstra D; Meenan RT; Lin JS; Maciosek MV
J Natl Cancer Inst; 2012 Dec; 104(23):1785-95. PubMed ID: 23197490
[TBL] [Abstract][Full Text] [Related]
11. KRAS early testing: consensus initiative and cost-effectiveness evaluation for metastatic colorectal patients in an Italian setting.
Barone C; Pinto C; Normanno N; Capussotti L; Cognetti F; Falcone A; Mantovani L
PLoS One; 2014; 9(1):e85897. PubMed ID: 24465771
[TBL] [Abstract][Full Text] [Related]
12. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer.
Tappenden P; Jones R; Paisley S; Carroll C
Health Technol Assess; 2007 Mar; 11(12):1-128, iii-iv. PubMed ID: 17346499
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
Au HJ; Karapetis CS; O'Callaghan CJ; Tu D; Moore MJ; Zalcberg JR; Kennecke H; Shapiro JD; Koski S; Pavlakis N; Charpentier D; Wyld D; Jefford M; Knight GJ; Magoski NM; Brundage MD; Jonker DJ
J Clin Oncol; 2009 Apr; 27(11):1822-8. PubMed ID: 19273701
[TBL] [Abstract][Full Text] [Related]
14. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
15. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab.
De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S
JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259
[TBL] [Abstract][Full Text] [Related]
16. Influence of pharmacogenomic profiling prior to pharmaceutical treatment in metastatic colorectal cancer on cost effectiveness : a systematic review.
Frank M; Mittendorf T
Pharmacoeconomics; 2013 Mar; 31(3):215-28. PubMed ID: 23338963
[TBL] [Abstract][Full Text] [Related]
17. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
Fragoulakis V; Papagiannopoulou V; Kourlaba G; Maniadakis N; Fountzilas G
Clin Ther; 2012 Oct; 34(10):2132-42. PubMed ID: 23063374
[TBL] [Abstract][Full Text] [Related]
18. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
[TBL] [Abstract][Full Text] [Related]
19. KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Huang YF; Yang ZY; Zheng DY; Chen JZ; Tang JL
Cancer; 2013 Feb; 119(4):714-21. PubMed ID: 22972628
[TBL] [Abstract][Full Text] [Related]
20. Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer.
Dahabreh IJ; Terasawa T; Castaldi PJ; Trikalinos TA
Ann Intern Med; 2011 Jan; 154(1):37-49. PubMed ID: 21200037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
